drugset / Trial / NCT00616915

Does Sleep Quality Change After Switch From Wellbutrin SR to Wellbutrin XL in Patients With Major Depressive Disorder?

NCT00616915

Phase 1 Completed 20 enrolled Queen's University
Non-randomizedSingle-groupOpen-labelTreatment

Summary

Wellbutrin (bupropion) is an effective antidepressant (Thase, M 2005). It exists in instant release (IR), sustained release (SR) and extended release (XL) forms. The IR formulation was never approved for use in Canada. The XL formulation allows for once daily dosing. Wellbutrin is both a norepinephrine and dopamine reuptake inhibitor, and as such increases the synaptic concentration of both neurotransmitters. This adds to its positive effects on cognition, apathy, tiredness and executive functioning. The increased activation may be also responsible for some of its side effects such as initial insomnia and reduced sleep efficiency, especially when taken at night.

Timeline

Start
2007-01
Primary completion
2009-01
Completion
2010-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Bupropion Small molecule 300 mg

Indications